DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "US Procedure Numbers for Diabetes Monitoring, Treatment and Drug Delivery 2017 - MedPro" report to their offering.
Diabetes mellitus is a multifaceted disease that yields various approaches in terms of diagnosis, treatment and drug delivery. Products for maintenance and treatment of diabetes can be of high volume and low cost or of relatively low volume and high cost.
The U.S. diabetes monitoring, treatment and drug delivery market increased in value in 2016 and growth is expected to persist over the forecast period. Growth will be driven by the increasing prevalence of diabetes in the U.S. and technological advancements made in certain segments, particularly insulin pumps and continuous glucose monitoring (CGM).
Limitations to market growth include pricing pressure due to recent CMS reimbursement changes and the negative impact on the overall blood glucose monitoring market. The recent influx of low-price competitors in the blood glucose test strip segment has also placed downward pressure on prices and resulted in market value contractions despite the growing volume and increasing number of diabetics testing their blood glucose levels.
Key Topics Covered:
Table Of Contents I
List Of Figures Iii
List Of Charts Iv
Executive Summary
U.S. Diabetes Monitoring, Treatment And Drug Delivery Market Overview
Competitive Analysis
Market Trends
Market Developments
Procedure Numbers
Procedure Codes Investigated
Markets Included
Key Report Updates
Version History
Research Methodology
Companies Mentioned
Sanofi
Novo Nordisk
Eli Lilly
Medtronic
Johnson & Johnson
Becton Dickinson
Abbott
Roche
DexCom
Ascensia
Insulet
Trividia Health
Tandem
Nova Biomedical
Valeritas
For more information about this report visit http://www.researchandmarkets.com/research/4sh7rr/us_procedure
